CN113164419A - Eif4e抑制剂和其用途 - Google Patents

Eif4e抑制剂和其用途 Download PDF

Info

Publication number
CN113164419A
CN113164419A CN201980069765.1A CN201980069765A CN113164419A CN 113164419 A CN113164419 A CN 113164419A CN 201980069765 A CN201980069765 A CN 201980069765A CN 113164419 A CN113164419 A CN 113164419A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
cancer
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980069765.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·萨哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Medical Co
Original Assignee
Pike Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Medical Co filed Critical Pike Medical Co
Publication of CN113164419A publication Critical patent/CN113164419A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980069765.1A 2018-09-07 2019-09-06 Eif4e抑制剂和其用途 Pending CN113164419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728372P 2018-09-07 2018-09-07
US62/728,372 2018-09-07
PCT/US2019/049903 WO2020051424A1 (en) 2018-09-07 2019-09-06 Eif4e inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN113164419A true CN113164419A (zh) 2021-07-23

Family

ID=69723288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069765.1A Pending CN113164419A (zh) 2018-09-07 2019-09-06 Eif4e抑制剂和其用途

Country Status (5)

Country Link
US (1) US12030875B2 (enExample)
EP (1) EP3846793B1 (enExample)
JP (1) JP2022500499A (enExample)
CN (1) CN113164419A (enExample)
WO (1) WO2020051424A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) * 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
WO2024112894A1 (en) * 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463071A (en) * 1991-07-27 1995-10-31 Dr. Karl Thomae Gmbh 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds
CN1176101A (zh) * 1996-07-19 1998-03-18 弗·哈夫曼-拉罗切有限公司 N－(4－芳基－噻唑－2－基)－磺胺衍生物及其用途
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905119A1 (de) * 1989-02-20 1990-08-23 Bayer Ag Substituierte acrylsaeureester
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US5654322A (en) 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
US5457004A (en) 1994-05-27 1995-10-10 Eastman Kodak Company Photographic element containing a high dye-yield coupler with methine dye chromophore
EP0790057B1 (en) 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE19618528A1 (de) 1996-05-08 1997-11-13 Basf Ag Methin- und Azamethinfarbstoffe auf Basis von Trifluormethylpyridonen
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
KR100479137B1 (ko) 1999-12-02 2005-03-31 노파르티스 아게 살충제 및 항기생충제로서의 아미노헤테로시클릴아미드
WO2001046165A2 (en) 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
JP2001269010A (ja) 2000-03-27 2001-10-02 Iseki & Co Ltd ロ−タリの尾輪等取付装置
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6667326B1 (en) 2000-11-16 2003-12-23 Novartis Animal Health Us, Inc. Pesticidal aminoheterocyclamide compounds
CA2430037A1 (en) 2000-11-20 2002-05-30 Michael S. South Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0214139D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
US20050227989A1 (en) 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
NZ550114A (en) * 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
KR20060017929A (ko) 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1868604B1 (en) 2005-01-21 2014-08-13 President and Fellows of Harvard College Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
US7786040B2 (en) 2005-02-24 2010-08-31 Nihon Nohyaku Co., Ltd. 4-cyclopropyl-1,2,3,-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
TWI410406B (zh) 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
DE102005062991A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP5236499B2 (ja) 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
CA2637336A1 (en) 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind. Co., Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
JP2007254317A (ja) 2006-03-22 2007-10-04 Nippon Nohyaku Co Ltd 増収剤及びその使用方法
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
EP2007393B1 (en) 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
JP5219465B2 (ja) 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
KR101047614B1 (ko) 2007-07-27 2011-07-07 동화약품주식회사 신규한 벤즈아미딘 유도체, 이의 제조방법 및 이를포함하는 골다공증의 예방 또는 치료용 약학 조성물
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
KR20100090250A (ko) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8008329B2 (en) 2008-08-01 2011-08-30 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate
KR20100014090A (ko) 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
WO2010012793A1 (en) 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010025142A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
WO2010025870A1 (en) 2008-09-03 2010-03-11 Bayer Cropscience Ag Synergistic combinations of thiadiazol carbonic acid derivatives
MX2011006006A (es) 2008-12-08 2011-09-08 Euroscreen Sa Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
GB0900388D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
EP2507232B1 (en) * 2009-12-04 2019-03-20 National Health Research Institutes Proline derivatives
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
WO2011076732A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
WO2011076734A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
AT510456B1 (de) 2010-09-27 2012-11-15 Univ Wien Tech Thiazolamin-derivate als zelldifferenzierungsbeschleuniger
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2826067A1 (en) 2011-02-10 2012-08-16 Novartis Ag Isoxazoline derivatives for controlling invertebrate pests
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2836474A1 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9073881B2 (en) * 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
EP2760856B1 (en) 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selective nr2b antagonists
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CN103159695B (zh) 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
CN102532050A (zh) 2011-12-20 2012-07-04 中国科学院兰州化学物理研究所 一种2-胺基取代的噁(噻)唑衍生物的制备方法
US9732051B2 (en) 2011-12-23 2017-08-15 Basf Se Isothiazoline compounds for combating invertebrate pests
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013157540A1 (ja) 2012-04-17 2013-10-24 富士フイルム株式会社 含窒素複素環化合物またはその塩
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
CN103420991B (zh) 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014159938A1 (en) 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
EP3024898B1 (en) 2013-07-25 2017-11-08 OMG UK Technology Limited Encapsulated catalysts
WO2015050984A1 (en) 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
WO2016022644A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
JP6707630B2 (ja) 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3481831B1 (en) 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
CN106317050B (zh) 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
CN108473487B (zh) 2016-12-13 2021-08-03 普林斯顿药物研发公司 一种蛋白激酶抑制剂
WO2018157857A1 (zh) 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
WO2019134661A1 (zh) 2018-01-03 2019-07-11 南京明德新药研发股份有限公司 异吲哚啉酮及其衍生物作为csf-1r抑制剂
WO2019233456A1 (zh) 2018-06-08 2019-12-12 贝达药业股份有限公司 Erk抑制剂及其应用
EP3814324A4 (en) 2018-06-30 2021-08-25 National Institute Of Biological Sciences, Beijing CATHEPSIN C INHIBITORS
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN109456279B (zh) 2018-10-12 2022-11-22 南华大学 噻唑氨基苯甲酰胺乙酸酯衍生物及其用途
CN109232467B (zh) 2018-10-12 2022-11-25 南华大学 噻唑氨基苯甲酸衍生物及其用途
CN109320473B (zh) 2018-10-17 2022-11-22 南华大学 噻唑氨基苯甲酰胺乙酸衍生物及其用途
EP3643713B1 (en) 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
CN110759835B (zh) 2018-12-06 2023-05-30 广州华睿光电材料有限公司 苝醌类有机化合物及其应用
CN111484479B (zh) 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN111647000B (zh) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
WO2020198710A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN112778283B (zh) 2019-11-08 2023-02-03 北京夏禾科技有限公司 有机电致发光材料及其器件
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
WO2021211974A1 (en) 2020-04-18 2021-10-21 Inipharm, Inc. Hsd17b13 inhibitors and uses thereof
EP3901151B1 (en) 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
CN115720579A (zh) 2020-05-01 2023-02-28 赛丹思科大学 抗细菌和抗真菌的截短侧耳素缀合物
US20240124406A1 (en) 2020-06-03 2024-04-18 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
PY2157405A (es) 2020-07-15 2022-04-22 Ifm Due Inc Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4221701A1 (en) 2020-09-30 2023-08-09 FL2022-001, Inc. Hsd17b13 inhibitors and uses thereof
US20240246977A1 (en) 2020-12-31 2024-07-25 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463071A (en) * 1991-07-27 1995-10-31 Dr. Karl Thomae Gmbh 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds
CN1176101A (zh) * 1996-07-19 1998-03-18 弗·哈夫曼-拉罗切有限公司 N－(4－芳基－噻唑－2－基)－磺胺衍生物及其用途
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS: "RN：898390-37-9", STN REGISTRY数据库, 3 August 2006 (2006-08-03), pages 1 *
YUJIA DAI, 等: "A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units", BIOORG MED CHEM LETT ., vol. 21, no. 13, 3 November 2003 (2003-11-03), pages 3817 - 20, XP002555649, DOI: 10.1016/j.bmcl.2003.07.012 *
刘勇;方勇;汪辉;马丁;: "雷帕霉素在顺铂诱导HeLa细胞凋亡中的协同作用", 华中医学杂志, no. 06, 20 December 2009 (2009-12-20), pages 6 - 9 *
周育奇，等: "PIM-1激酶抑制剂研究进展", 中国新药杂志 ., vol. 28, no. 01, 31 January 2019 (2019-01-31), pages 49 - 53 *

Also Published As

Publication number Publication date
US20220089587A1 (en) 2022-03-24
US12030875B2 (en) 2024-07-09
JP2022500499A (ja) 2022-01-04
EP3846793B1 (en) 2024-01-24
EP3846793A1 (en) 2021-07-14
WO2020051424A1 (en) 2020-03-12
EP3846793A4 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
US11332470B2 (en) CXCR4 inhibitors and uses thereof
US20210363139A1 (en) Cxcr4 inhibitors and uses thereof
CN114502540A (zh) Tead抑制剂和其用途
US12157731B2 (en) EIF4E inhibitors and uses thereof
US12030875B2 (en) EIF4E inhibitors and uses thereof
JP7304892B2 (ja) 抗増殖性化合物およびその使用
US20240092779A1 (en) Usp1 inhibitors and uses thereof
US20250326746A1 (en) Eif4e inhibitors and uses thereof
US20240174665A1 (en) Cdk2 inhibitors and uses thereof
CN114206869A (zh) Cxcr4抑制剂和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723